Clinical Trial Update: Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating basiliximab with ruxolitinib as second-line treatment for grade 3-4 steroid-resistant acute graft-versus-host disease (aGVHD) focusing …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Basiliximab (basiliximab)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Safety and Efficacy | Phase 4 | Status: UNKNOWN